arrow
S

Sara Saberi

university of michigan
H指数:35
被引数:7,244

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM

Aficamten在非梗阻性肥厚型心肌病患者的安全性与有效性:FOREST-HCM研究96周分析

2025-09-280
OAAI
Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks

接受Mavacamten治疗长达128周的梗阻性肥厚型心肌病患者长期有利的心脏重塑

2025-09-160
PRE
Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials

梗阻性肥厚型心肌病患者使用Aficamten治疗后房颤发生率低:REDWOOD-HCM、SEQUOIA-HCM和FOREST-HCM试验的分析

2025-08-310
OAAI
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Aficamten 治疗:有症状性梗阻性肥厚型心肌病

2025-06-190
PRE
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy

阿菲坎坦与丙吡胺联用治疗症状性梗阻性肥厚型心肌病

2025-04-020
OAAI
Sex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy
2025-02-010
PRE
Association Between age or Duration of Diagnosis in Obstructive Hypertrophic Cardiomyopathy and Response to Mavacamten Treatment: Exploratory Analysis of the EXPLORER-HCM Trial

梗阻性肥厚型心肌病中年龄或确诊时间与Mavacamten治疗反应关系的关联:EXPLORER-HCM试验的探索性分析

2024-12-070
PRE
Limited Concordance of Left Ventricular Ejection Fraction and Chamber Dimensions With Automated Assessments in Hypertrophic Cardiomyopathy: A Substudy From VALORHCM

左心室射血分数和心腔尺寸与自动化评估的有限一致性:VALORHCM研究的亚研究

2024-12-010
PRE
Efficacy and Safety of Aficamten in Patients Guideline-Eligible for Septal Reduction Therapy in the FOREST-HCM Trial

Aficamten在FOREST-HCM试验中,对符合室间隔减容治疗指南适应证患者的疗效与安全性

2024-11-120
PRE
Social Determinants of Health and Outcomes in Patients with Hypertrophic Cardiomyopathy in the Sarcomeric Human Cardiomyopathy Registry (SHaRe)

肌节性心肌病注册研究(SHaRe)中肥厚型心肌病患者的健康社会决定因素与结局

2024-11-120
PRE
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

Aficamten在症状性非梗阻性肥厚型心肌病中的疗效和安全性: 来自REDWOOD-HCM试验的结果,队列4

2024-11-017
OAAI
Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry
2024-10-220
PRE
Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM

aficamten在非梗阻性肥厚型心肌病患者中的安全性和有效性: forest-hcm的36周分析

2024-07-183
OA
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
2024-06-0443
PRE